Two Sigma Investments’s Grace Therapeutics GRCE Stock Holding History

Two Sigma Investments’s Portfolio GRCE Stock Details GRCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$220K	Buy	+96,890	New	+$268K	﹤0.01%	4726

Other funds holding GRCE

Cerity Partners New York $82.7B AUM 28.53% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Maven Securities St Helier, Jersey $5.06B AUM 59.27% 1-Year Est. Return

Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return

Cantor Fitzgerald New York $9.23B AUM 74.49% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Two Sigma Investments's GRCE Position: Q2 2026 in Review

Two Sigma Investments opened a new position in Grace Therapeutics (GRCE) in Q2 2026: 96,890 shares worth $220K. The stake represents ﹤0.01% of the portfolio and ranks #4726 among its holdings.

31 funds tracked by Wall St. Rank hold GRCE as of Q2 2026.

Two Sigma Investments held 96,890 shares of Grace Therapeutics worth $220K as of Q2 2026.
Grace Therapeutics was a new Two Sigma Investments position in Q2 2026.
Grace Therapeutics made up ﹤0.01% of Two Sigma Investments's portfolio in Q2 2026, its #4726 holding.
31 funds tracked by Wall St. Rank held Grace Therapeutics as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.